Is this wording new? TKIs as the drug?I may be wrong, but is this the first time they've specifically mentioned TKIs as a drug that will work with this peptide? I do recall them saying something to the effect that they would be testing it in leukemia and lymphatic cancers. Perhaps that will be with a TKI? If so, a whole nother massive market would open up. Just saying.
from today's PR:
"..Commercially available anticancer drugs, like docetaxel, doxorubicin or tyrosine kinase inhibitors are conjugated to Theratechnologies’ investigational novel peptide to specifically target sortilin receptors. This could potentially improve the efficacy and safety of those agents."